Vor Biopharma Inc. (NYSE:VOR – Get Rating) – Equities researchers at HC Wainwright decreased their FY2022 earnings per share (EPS) estimates for shares of Vor Biopharma in a report released on Monday, November 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($2.50) per share for the year, down from their prior estimate of ($2.35). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q4 2022 earnings at ($0.67) EPS, Q1 2023 earnings at ($0.69) EPS, Q2 2023 earnings at ($0.71) EPS, Q3 2023 earnings at ($0.55) EPS, Q4 2023 earnings at ($0.56) EPS, FY2023 earnings at ($2.46) EPS, FY2024 earnings at ($2.37) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($1.34) EPS.
A number of other research analysts also recently commented on the stock. Oppenheimer decreased their price objective on shares of Vor Biopharma from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. Wedbush reissued an “initiates” rating on shares of Vor Biopharma in a research report on Tuesday, July 26th. Finally, Barclays cut their price objective on Vor Biopharma from $26.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, November 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.00.
Vor Biopharma Trading Down 2.4 %
Institutional Investors Weigh In On Vor Biopharma
A number of large investors have recently bought and sold shares of VOR. Jane Street Group LLC acquired a new stake in Vor Biopharma during the third quarter worth about $41,000. Bourgeon Capital Management LLC boosted its stake in shares of Vor Biopharma by 39.0% in the 3rd quarter. Bourgeon Capital Management LLC now owns 10,700 shares of the company’s stock valued at $43,000 after purchasing an additional 3,000 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at approximately $58,000. Virtu Financial LLC acquired a new stake in shares of Vor Biopharma in the 2nd quarter valued at approximately $61,000. Finally, Corton Capital Inc. boosted its stake in shares of Vor Biopharma by 37.6% in the 2nd quarter. Corton Capital Inc. now owns 14,856 shares of the company’s stock valued at $74,000 after purchasing an additional 4,061 shares in the last quarter. 81.87% of the stock is currently owned by institutional investors and hedge funds.
About Vor Biopharma
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
- Get a free copy of the StockNews.com research report on Vor Biopharma (VOR)
- International Game Technology is Well Worth the Gamble
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Use The Airbnb Stock Implosion to Your Advantage
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.